COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burtโs Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
์ข
๋ชฉ ์ฝ๋ CSCI
ํ์ฌ ์ด๋ฆCOSCIENS Biopharma Inc
์์ฅ์ผDec 19, 1995
CEOMs. Anna Biehn
์ง์ ์- -
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃDec 19
์ฃผ์C/O Norton Rose Fulbright Canada Llp
๋์TORONTO
์ฆ๊ถ ๊ฑฐ๋์The Toronto Stock Exchange
๊ตญ๊ฐCanada
์ฐํธ ๋ฒํธM5K 1E7
์ ํ18439003201
์น์ฌ์ดํธhttps://www.cosciensbio.com/
์ข
๋ชฉ ์ฝ๋ CSCI
์์ฅ์ผDec 19, 1995
CEOMs. Anna Biehn
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์